Joint Clinical Trials Office

You are here

A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors (TVEC 20140318)

Clinical Trial Details

Contact

Alice F. Mercado, RN, MBA, CCRC
alm2051@med.cornell.edu
646.962.3080

Primary Investigator

Elizabeta C. Popa, M.D.

Protocol ID(s)

Weill Cornell Medicine IRB #:

1602017031

Status:

Open to Enrollment

Disease

Drug/Device

Drug

Study Type

Phase

1